Get the Stockscreener App
11.05
4.99%
-0.58
Pre-market:
11.30
0.25
+2.26%
Cvrx Inc stock is traded at $11.05, with a volume of 108.93K.
It is down -4.99% in the last 24 hours and down -23.74% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$11.63
Open:
$11.6
24h Volume:
108.93K
Relative Volume:
0.50
Market Cap:
$287.70M
Revenue:
$47.26M
Net Income/Loss:
$-58.48M
P/E Ratio:
-4.0852
EPS:
-2.7049
Net Cash Flow:
$-40.45M
1W Performance:
-4.58%
1M Performance:
-23.74%
6M Performance:
+40.76%
1Y Performance:
-49.47%
1-Day Range:
$10.93
$11.63
1-Week Range:
$10.76
$11.96
52-Week Range:
$6.40
$22.45
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
11.05 | 287.70M | 47.26M | -58.48M | -40.45M | -2.7049 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
(CVRX) Trading Report - Stock Traders Daily
With A 29% Price Drop For CVRx, Inc. (NASDAQ:CVRX) You'll Still Get What You Pay For - Simply Wall St
Power Shift 25: Medtech firm's new CEO looks to 'build a world-class team' - The Business Journals
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Analyzing Co-Diagnostics (NASDAQ:CODX) and CVRx (NASDAQ:CVRX) - Defense World
CVRx, Inc. (NASDAQ:CVRX) Short Interest Down 9.8% in January - Defense World
CVRx, Inc. SEC 10-K Report - TradingView
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - MSN
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com UK
(CVRX) Long Term Investment Analysis - Stock Traders Daily
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim - GlobeNewswire
Cvrx, Inc. Announces New Real-World Evidence Demonstrating Significant Reductions in Healthcare Utility with Barostim - Marketscreener.com
CVRx, Inc. Presents New Real-World Evidence Demonstrating Significant Reductions in Hospital Visits After Barostim Implantation at THT Conference 2025 - Nasdaq
Institutional owners may take dramatic actions as CVRx, Inc.'s (NASDAQ:CVRX) recent 10% drop adds to one-year losses - Simply Wall St
CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Cantor Fitzgerald Has Negative View of CVRx FY2025 Earnings - MarketBeat
William Blair Weighs in on CVRx's Q2 Earnings (NASDAQ:CVRX) - MarketBeat
Piper Sandler Forecasts Strong Price Appreciation for CVRx (NASDAQ:CVRX) Stock - MarketBeat
CVRx (NASDAQ:CVRX) Price Target Raised to $23.00 at Canaccord Genuity Group - MarketBeat
Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know - MSN
William Blair Weighs in on CVRx’s Q2 Earnings (NASDAQ:CVRX) - Defense World
FY2025 EPS Estimates for CVRx Cut by Cantor Fitzgerald - Defense World
CVRx (NASDAQ:CVRX) Issues Quarterly Earnings Results - MarketBeat
CVRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
Skechers Posts Downbeat Results, Joins e.l.f. Beauty, LiveRamp And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
FY2025 EPS Estimates for CVRx Decreased by Cantor Fitzgerald - Armenian Reporter
Calamos Advisors LLC Makes New Investment in CVRx, Inc. (NASDAQ:CVRX) - ETF Daily News
Canaccord Genuity Group Boosts CVRx (NASDAQ:CVRX) Price Target to $23.00 - Defense World
CVRx targets $63M-$65M revenue in 2025 with strengthened sales strategy - MSN
Piper Sandler Raises CVRx (NASDAQ:CVRX) Price Target to $20.00 - Defense World
CVRx Inc [CVRX] Shares Fall -7.20 % on Wednesday - Knox Daily
Should You Invest in CVRx Inc (CVRX) Now? - The News Heater
CVRx’s Earnings Call: Growth Amid Challenges - TipRanks
What 4 Analyst Ratings Have To Say About CVRx - Benzinga
CVRx stock dips on Q4 EPS miss - Mass Device
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates - MSN
Objective long/short (CVRX) Report - Stock Traders Daily
CVRx Announces Strong Revenue Growth in 2024 - TipRanks
CVRx, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Earnings call transcript: CVRx Q4 2024 shows revenue growth, stock dips - MSN
CVRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire
CVRx: Q4 Earnings Snapshot -February 04, 2025 at 04:50 pm EST - Marketscreener.com
CVRx: Q4 Earnings Snapshot - Leader-Telegram
Earnings Flash (CVRX) CVRX INC. Reports Q4 Revenue $15.3M, vs. FactSet Est of $15.1M - Marketscreener.com
CVRx Earnings Showcase: Heart Failure Treatment Propels 41% Revenue Explosion in Core Market - StockTitan
CVRx, Inc. (NASDAQ:CVRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
CVRx Inc (CVRX) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):